Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SBT 020

Drug Profile

SBT 020

Alternative Names: SBT-020; SBT-020-01; SBT-20; SS 20 - Stealth BioTherapeutics; SS-20

Latest Information Update: 03 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stealth BioTherapeutics
  • Class Neuroprotectants
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Huntington's disease
  • Preclinical Peripheral nervous system diseases
  • No development reported CNS disorders

Most Recent Events

  • 28 Feb 2019 No recent reports of development identified for preclinical development in CNS-disorders in USA (SC)
  • 01 Dec 2018 Preclinical trials in Peripheral nervous system diseases in USA (unspecified route)
  • 28 Nov 2018 No recent reports of development identified for phase-I development in Huntington's-disease(In volunteers) in United Kingdom (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top